Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.38 |
| ▸ | ADCY5 | O95622 | 6/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | NNMT | P40261 | 8/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7156164 | 0.85 | ADCY5 (0.47) | PRMT5WDR77ADCY5NR1I2ALB | |
| SCHEMBL7114896 | 0.85 | ADCY5 (0.47) | PRMT5WDR77ADCY5NR1I2ALB | |
| SCHEMBL7156161 | 0.85 | ADCY5 (0.47) | PRMT5WDR77ADCY5NR1I2ALB | |
| SCHEMBL23692929 | 0.83 | PRMT5 (0.42) | PRMT5WDR77SLC22A12NNMT | |
| SCHEMBL31123772 | 0.83 | PRMT5 (0.42) | PRMT5WDR77SLC22A12NNMT | |
| SCHEMBL7592748 | 0.78 | ADCY5 (0.54) | ADCY5NR1I2ALBPDE4D | |
| SCHEMBL30969135 | 0.78 | ADCY5 (0.54) | ADCY5NR1I2ALBPDE4D | |
| SCHEMBL5994923 | 0.78 | ADCY5 (0.54) | ADCY5NR1I2ALBPDE4D | |
| SCHEMBL7592747 | 0.78 | ADCY5 (0.54) | ADCY5NR1I2ALBPDE4D | |
| SCHEMBL6553481 | 0.78 | ADCY5 (0.54) | ADCY5NR1I2ALBPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045508-A1 | (1r,cis)-4-(4-amino-7h-pyrrolo'2,3-i(d) pyrimidine-7-yl)-2-cyclopentene-1-methanol derivatives as antiviral | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | disclosed |
| EP-1235834-A1 | (1R,CIS)-4-(4-AMINO-7H-PYRR0L0[2,3- I(D)]PYRIMIDINE-7-YL)-2-CYCLOPENTENE-1-METHANOL DERIVATIVES AS ANTIVIRAL | GLAXO GROUP LIMITED (GB) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001042255-A1 | (1R,CIS)-4-(4-AMINO-7H-PYRROLO'2,3-I(D) ! PYRIMIDINE-7-YL)-2-CYCLOPENTENE-1-METHANOL DERIVATIVES AS ANTIVIRAL | GLAXO GROUP LIMITED (GB) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045508-A1 | (1r,cis)-4-(4-amino-7h-pyrrolo'2,3-i(d) pyrimidine-7-yl)-2-cyclopentene-1-methanol derivatives as antiviral | MAVS, ZC3HAV1, SARS1 | PRMT5 879/4885WDR77 317/4885ADCY5 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.